VITAL CAPITAL LIMITED 2003-06-02 ASX-SIGNAL-GHOMEX -...

VITAL CAPITAL LIMITED 2003-06-02 ASX-SIGNAL-G

HOMEX - Melbourne

+++++++++++++++++++++++++
Melbourne biotechnology company Vital Health Sciences Limited (VHS)
in collaboration with Monash University, today announced results of a
study that showed VHS's patented vitamin E product is able to inhibit
the growth of cells known to be implicated in causing heart disease.

The study was conducted by Paragon Bioservices at the prestigious
Johns Hopkins University in the United States.

Dr. Robert Gianello of Monash University, Department of Biochemistry
and Molecular Biology says, "Initial results from tests on the
anti-proliferative activity of VHS patented form of vitamin E have
been very promising.

"VHS vitamin E caused an 89% inhibition of cells compared to 43%
observed with standard vitamin E (see figure 1). This indicates the
potential for using the VHS product to reduce the risk of the
cardiovascular disease, known as atherosclerosis.

"Our studies demonstrate that the VHS product has potent
anti-proliferative properties. Importantly, the study also
demonstrated that the anti-proliferative action of VHS vitamin E was
far more effective than current vitamin E."

Heart disease, including atherosclerosis, is the leading cause of
death in the Western World. Atherosclerosis is partly due to
excessive cell proliferation in the large blood vessels of the heart
and VHS vitamin E is a potent inhibitor of these cells.

Associate Professor Andrew Vizard, Chairman of Vital Capital Limited
(35.5% shareholder in VHS), says, "Retail sales in North America of
vitamin E dietary supplements are estimated to be US$1.2 billion.
Sales of vitamin E are driven by heavily promoted health benefits
including the prevention of cardiovascular disease.

"Since VHS's patented vitamin E shows superior benefits in these
laboratory experiments compared to currently available vitamin E, we
expect the VHS product to gain significant market penetration."

Professor Vizard says, "Commercial discussions by VHS with global
distributors based in North America are currently underway, and we
are advised that work is well advanced to support regulatory approval
by the US Food & Drug Administration (FDA). VHS expects sales into
the dietary supplement market to commence in the first quarter of
2004."

Figure 1. Paragon Bioservices' research showing inhibition of cell
proliferation VHS vitamin E versus standard vitamin E.

(GRAPH)

The graph demonstrates that VHS vitamin E was a superior inhibitor of
cell proliferation (89% inhibition) compared to standard vitamin E
(43% inhibition).

ABOUT VITAL HEALTH SCIENCES LTD

Vital Health Sciences (VHS) is a biotechnology company engaged in
research, discovery and development of human and animal therapeutics
and is 35.5% owned by Vital Capital Limited (traded on the Australian
Stock Exchange under the code VIT). Please visit www.vitalhs.com.

Studies were conducted by Paragon Bioservices at Johns Hopkins
University. www.paragonbioservices.com

For more information contact:

Robert Gianello Adam Soffer
MONASH UNIVERSITY PUBLIC RELATIONS EXCHANGE
03 9905 5325 03 9607 4500
0412 966 335

Associate Professor Andrew Vizard
CHAIRMAN
Vital Capital Limited
03 9605 5900

A copy of Figure 1; and Questions & Answers is available in PDF
format on www.asx.com.au. Alternatively it is available for purchase
from ASX Customer Service on 1 300 300 279.